Dicks Sporting Goods Inc vs Cassava Sciences Inc — how do they compare? Dicks Sporting Goods Inc trades at $135.31 (market cap $13.26B), while Cassava Sciences Inc trades at $0.84 (market cap $39.40M). The key difference: Dicks Sporting Goods Inc is far larger — about 336.5× Cassava Sciences Inc's market cap, and Dicks Sporting Goods Inc pays a 3.71% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Cassava Sciences Inc for 37 Days on average.
| DKS | FLNA | |
|---|---|---|
Market Cap | $13.26B | $39.40M |
Volume | 2,292,035 | 759,018 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $4.64 |
52-Week Low | $121.15 | $0.68 |
Typical Hold Time | 19 Days | 37 Days |
Enterprise Value | $20.31B | -$43.28M |
Dividend Yield | 3.71% | — |
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $134.91, up 2.84% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains solid fundamentals with a P/E of 14.86 and ROE of 18.47%, though recent earnings showed a Q2 2026 miss. Analyst consensus remains strongly positive with 56.9% buy ratings and a $153.30 price target, representing 13.6% upside potential from current levels.
While facing securities litigation headwinds, DKS demonstrates operational strength with $1.31B operating cash flow and consistent dividend payments. The stock offers value with attractive valuation metrics, but investors should monitor the ongoing class action lawsuits and potential impact on near-term sentiment despite the fundamentally sound business model.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →